Drug Manufacturing

Health Canada authorises Roche’s Vabysmo for certain eye conditions

Health Canada has granted authorisation to Roche Canada's Vabysmo (faricimab injection) to be used in a 6.0 mg single-use pre-filled syringe (PFS) for treating diabetic macular oedema, wet or neovascular, age-related macular degeneration (AMD), and macular oedema secondary to retinal vein occlusion (RVO).

Fermion and Simcere to partner on development of pain treatment drug

Guangzhou Fermion Technology and Simcere Pharmaceutical Group have announced a collaboration aiming to develop FZ002-037 for pain treatment.

Micron Biomedical secures funds for needle-free vaccine development

Micron Biomedical has secured over $16m in a Series A3 financing round to expand the commercial manufacturing of its needle-free vaccines.

Cycle expands MS treatment portfolio with Banner Life Sciences acquisition

Cycle Pharmaceuticals has completed the acquisition of Banner Life Sciences, including BAFIERTAM (monomethyl fumarate) product, a US Food and Drug Administration (FDA)-approved treatment for relapsing forms of multiple sclerosis (MS) in the adult population.

RheumaGen secures $15m in Series A funding to advance RA therapies

RheumaGen has secured $15m in Series A financing round to advance the development of a class of human leukocyte antigen (HLA) gene-editing therapies for autoimmune ailments including rheumatoid arthritis.

Star Therapeutics’ von Willebrand disease therapy gains FDA fast track status

Star Therapeutics' investigational monoclonal antibody, VGA039, has gained fast track designation from the US Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD).

Brii Biosciences acquires BRII-179 assets from VBI Vaccines

Brii Biosciences (Brii Bio) has entered into an agreement to acquire the intellectual property and other assets related to the Hepatitis B immunotherapeutic candidate, BRII-179 from VBI Vaccines (VBI) and its creditor K2 VBI Equity Trust and K2 HealthVentures.

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

WuXi Biologics (WuXi Bio) and Sino Biopharm have entered into a service agreement for the discovery of a monoclonal antibody (mAb) for a target that is not disclosed.

Axcelead DDP and Astellas partner for targeted protein degrader discovery

Axcelead Drug Discovery Partners (Axcelead DDP) has signed a drug discovery service agreement with Astellas Pharma for new candidate compounds for targeted protein degraders.